Skip to main content

11.04.2019 | Original Article

Association between changes in the mRNA expression of platelet-activating factor receptor in peripheral blood mononuclear cells and progression of diabetic nephropathy

verfasst von: Sahar Ghavidel Darestani, Mihoko Kurano, Atsushi Shinnakasu, Kiyoaki Yamamoto, Yukari Dochi, Kayo Uemura, Yuko Ikeda, Aiko Arimura, Hiroshi Arimura, Akira Kikuchi, Hiroshi Hashiguchi, Takahisa Deguchi, Yoshihiko Nishio

Erschienen in: Diabetology International

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Several studies have recently pointed out the role of many inflammatory mediators in the progression of diabetes complications. We had previously demonstrated that mRNA expression of platelet-activating factor receptor (PAFR) in peripheral blood mononuclear cells (PBMCs) was associated with urinary albumin to creatinine ratio (ACR) and forearm flow-mediated dilatation in patients with type 2 diabetes. In an attempt to elucidate this association, patients were followed up for 1 year.

Materials and methods

We recruited 95 patients from the hospital outpatient clinic, among whom 86 were followed up for 1 year (normoalbuminuria: 40 patients, microalbuminuria: 25 patients, macroalbuminuria: 21 patients). We then measured their baseline and 12 month characteristics and collected blood samples to extract PBMCs and measure gene expressions.

Results

Despite higher mRNA expression of PAFR in PBMCs among patients with macroalbuminuria, the rise in its value was not associated with biomarkers of nephropathy, while baseline values were not associated with progression of nephropathy. Moreover, changes in mRNA expression of PAFR were correlated with changes in ACR in all patients (r = 0.225, p = 0.037) and estimated glomerular filtration rate in patients with macroalbuminuria (r =  − 0.438, p = 0.047) during the follow-up period.

Conclusion

Our findings indicate that even though no causal relationship exists between diabetic nephropathy and elevated expression of PAFR in PBMCs, their close association signifies the presence of another common mechanism that could induce both events. Given these findings, the PAF/PAFR interaction could clarify corresponding mechanisms involved in diabetic complications.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Danaei G, Lu Y, Singh GM, et al. Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. Lancet Diabetes Endocrinol. 2014;2(8):634–47.CrossRef Danaei G, Lu Y, Singh GM, et al. Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. Lancet Diabetes Endocrinol. 2014;2(8):634–47.CrossRef
2.
Zurück zum Zitat Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS 64). Kidney Int. 2003;63(1):225–32.CrossRef Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS 64). Kidney Int. 2003;63(1):225–32.CrossRef
3.
Zurück zum Zitat Schiffrin EL, Lipman ML, Mann JFE. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116(1):85–97.CrossRef Schiffrin EL, Lipman ML, Mann JFE. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116(1):85–97.CrossRef
4.
Zurück zum Zitat Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421–426.CrossRef Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421–426.CrossRef
5.
Zurück zum Zitat Gaita D, Mihaescu A, Schiller A. Of heart and kidney: a complicated love story. Eur J Prev Cardiol. 2014;21(7):840–6.CrossRef Gaita D, Mihaescu A, Schiller A. Of heart and kidney: a complicated love story. Eur J Prev Cardiol. 2014;21(7):840–6.CrossRef
6.
Zurück zum Zitat Segall L, Nistor I, Covic A. Heart failure in patients with chronic kidney disease: a systematic integrative review. Biomed Res Int. 2014;2014:1–21.CrossRef Segall L, Nistor I, Covic A. Heart failure in patients with chronic kidney disease: a systematic integrative review. Biomed Res Int. 2014;2014:1–21.CrossRef
7.
Zurück zum Zitat Kurano M, Darestani SG, Shinnakasu A, et al. mRNA expression of platelet activating factor receptor (PAFR) in peripheral blood mononuclear cells is associated with albuminuria and vascular dysfunction in patients with type 2 diabetes. Diabetes Res Clin Pract. 2018;136:124–33.CrossRef Kurano M, Darestani SG, Shinnakasu A, et al. mRNA expression of platelet activating factor receptor (PAFR) in peripheral blood mononuclear cells is associated with albuminuria and vascular dysfunction in patients with type 2 diabetes. Diabetes Res Clin Pract. 2018;136:124–33.CrossRef
8.
Zurück zum Zitat Nakagawa T, Tanabe K, Croker BP, et al. Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nat Rev Nephrol. 2011;7(1):36–44.CrossRef Nakagawa T, Tanabe K, Croker BP, et al. Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nat Rev Nephrol. 2011;7(1):36–44.CrossRef
9.
Zurück zum Zitat Tziomalos K, Athyros VG. Diabetic nephropathy: new risk factors and improvements in diagnosis. Rev Diabet Stud. 2015;12(1–2):110–8.CrossRef Tziomalos K, Athyros VG. Diabetic nephropathy: new risk factors and improvements in diagnosis. Rev Diabet Stud. 2015;12(1–2):110–8.CrossRef
10.
Zurück zum Zitat Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164–76.CrossRef Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164–76.CrossRef
11.
Zurück zum Zitat Ismail N, Becker B, Strzelczyk P, Ritz E. Renal disease and hypertension in non–insulin-dependent diabetes mellitus. Kidney Int. 1999;55(1):1–28.CrossRef Ismail N, Becker B, Strzelczyk P, Ritz E. Renal disease and hypertension in non–insulin-dependent diabetes mellitus. Kidney Int. 1999;55(1):1–28.CrossRef
12.
Zurück zum Zitat Amini M, Safaei H, Aminorroaya A. The incidence of microalbuminuria and its associated risk factors in type 2 diabetic patients in Isfahan. Iran. Rev Diabet Stud. 2007;4(4):242–8.CrossRef Amini M, Safaei H, Aminorroaya A. The incidence of microalbuminuria and its associated risk factors in type 2 diabetic patients in Isfahan. Iran. Rev Diabet Stud. 2007;4(4):242–8.CrossRef
13.
Zurück zum Zitat Larkins RG, Dunlop ME. The link between hyperglycaemia and diabetic nephropathy. Diabetologia. 1992;35(6):499–504.CrossRef Larkins RG, Dunlop ME. The link between hyperglycaemia and diabetic nephropathy. Diabetologia. 1992;35(6):499–504.CrossRef
14.
Zurück zum Zitat Haneda M, Kikkawa R, Togawa M, et al. High blood pressure is a risk factor for the development of microalbuminuria in Japanese subjects with non-insulin-dependent diabetes mellitus. J Diabetes Complications. 1992 6(3):181–185.CrossRef Haneda M, Kikkawa R, Togawa M, et al. High blood pressure is a risk factor for the development of microalbuminuria in Japanese subjects with non-insulin-dependent diabetes mellitus. J Diabetes Complications. 1992 6(3):181–185.CrossRef
15.
Zurück zum Zitat Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334(1):13–8.CrossRef Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334(1):13–8.CrossRef
17.
Zurück zum Zitat Appel GB, Radhakrishnan J, Avram MM, et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care. 2003;26(5):1402–7.CrossRef Appel GB, Radhakrishnan J, Avram MM, et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care. 2003;26(5):1402–7.CrossRef
18.
Zurück zum Zitat Vivian E, Mannebach C. Therapeutic approaches to slowing the progression of diabetic nephropathy—Is less best? Drugs Context. 2013;2013:1–12.CrossRef Vivian E, Mannebach C. Therapeutic approaches to slowing the progression of diabetic nephropathy—Is less best? Drugs Context. 2013;2013:1–12.CrossRef
20.
Zurück zum Zitat Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329(20):1456–62.CrossRef Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329(20):1456–62.CrossRef
21.
Zurück zum Zitat Kawanami D, Matoba K, Takeda Y, Nagai Y, Akamine T. SGLT2 inhibitors as a therapeutic option for diabetic nephropathy. Int J Mol Sci. 2017;18(5):1083.CrossRef Kawanami D, Matoba K, Takeda Y, Nagai Y, Akamine T. SGLT2 inhibitors as a therapeutic option for diabetic nephropathy. Int J Mol Sci. 2017;18(5):1083.CrossRef
22.
Zurück zum Zitat Dieter BP, Alicic RZ, Tuttle KR. GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side. Am J Physiol Physiol. 2018;315(6):F1519–F15251525.CrossRef Dieter BP, Alicic RZ, Tuttle KR. GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side. Am J Physiol Physiol. 2018;315(6):F1519–F15251525.CrossRef
23.
Zurück zum Zitat Koya D, Campese VM. Statin use in patients with diabetes and kidney disease: the Japanese experience. J Atheroscler Thromb. 2013;20(5):407–24.CrossRef Koya D, Campese VM. Statin use in patients with diabetes and kidney disease: the Japanese experience. J Atheroscler Thromb. 2013;20(5):407–24.CrossRef
24.
Zurück zum Zitat Ting R-D, Keech AC, Drury PL, et al. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD study. Diabetes Care. 2012;35(2):218–25.CrossRef Ting R-D, Keech AC, Drury PL, et al. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD study. Diabetes Care. 2012;35(2):218–25.CrossRef
25.
Zurück zum Zitat Patel PS, Kearney JF. CD36 and platelet-activating factor receptor promote house dust mite allergy development. J Immunol. 2017;199(3):1184–95.CrossRef Patel PS, Kearney JF. CD36 and platelet-activating factor receptor promote house dust mite allergy development. J Immunol. 2017;199(3):1184–95.CrossRef
26.
Zurück zum Zitat Shiju TM, Mohan V, Balasubramanyam M, Viswanathan P. Soluble CD36 in plasma and urine: a plausible prognostic marker for diabetic nephropathy. J Diabetes Complications. 2015;29(3):400–6.CrossRef Shiju TM, Mohan V, Balasubramanyam M, Viswanathan P. Soluble CD36 in plasma and urine: a plausible prognostic marker for diabetic nephropathy. J Diabetes Complications. 2015;29(3):400–6.CrossRef
27.
Zurück zum Zitat Ruster C, Wolf G. The role of chemokines and chemokine receptors in diabetic nephropathy. Front Biosci. 2008;13:944–55.CrossRef Ruster C, Wolf G. The role of chemokines and chemokine receptors in diabetic nephropathy. Front Biosci. 2008;13:944–55.CrossRef
28.
Zurück zum Zitat Axelrad TW, Deo DD, Ottino P, et al. Platelet-activating factor (PAF) induces activation of matrix metalloproteinase 2 activity and vascular endothelial cell invasion and migration. FASEB J. 2004;18(3):568–70.CrossRef Axelrad TW, Deo DD, Ottino P, et al. Platelet-activating factor (PAF) induces activation of matrix metalloproteinase 2 activity and vascular endothelial cell invasion and migration. FASEB J. 2004;18(3):568–70.CrossRef
29.
Zurück zum Zitat Ding H-L, Xu M-T, Guo Y, et al. Effect of losartan on the mRNA expressions of MT3-MMP and TIMP-2 in diabetic kidneys. Rev Diabet Stud. 2005;2(4):216–216.CrossRef Ding H-L, Xu M-T, Guo Y, et al. Effect of losartan on the mRNA expressions of MT3-MMP and TIMP-2 in diabetic kidneys. Rev Diabet Stud. 2005;2(4):216–216.CrossRef
30.
Zurück zum Zitat Correa-Costa M, Andrade-Oliveira V, Braga TT, et al. Activation of platelet-activating factor receptor exacerbates renal inflammation and promotes fibrosis. Lab Invest. 2014;94(4):455–66.CrossRef Correa-Costa M, Andrade-Oliveira V, Braga TT, et al. Activation of platelet-activating factor receptor exacerbates renal inflammation and promotes fibrosis. Lab Invest. 2014;94(4):455–66.CrossRef
31.
Zurück zum Zitat Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond). 2013;124(3):139–52.CrossRef Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond). 2013;124(3):139–52.CrossRef
32.
Zurück zum Zitat Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation. 2004;110(1):32–5.CrossRef Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation. 2004;110(1):32–5.CrossRef
33.
Zurück zum Zitat Ishii S, Shimizu T. Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. Prog Lipid Res. 2000;39(1):41–82.CrossRef Ishii S, Shimizu T. Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. Prog Lipid Res. 2000;39(1):41–82.CrossRef
34.
Zurück zum Zitat Montrucchio G, Alloatti G, Camussi G. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev. 2000;80(4):1669–99.CrossRef Montrucchio G, Alloatti G, Camussi G. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev. 2000;80(4):1669–99.CrossRef
Metadaten
Titel
Association between changes in the mRNA expression of platelet-activating factor receptor in peripheral blood mononuclear cells and progression of diabetic nephropathy
verfasst von
Sahar Ghavidel Darestani
Mihoko Kurano
Atsushi Shinnakasu
Kiyoaki Yamamoto
Yukari Dochi
Kayo Uemura
Yuko Ikeda
Aiko Arimura
Hiroshi Arimura
Akira Kikuchi
Hiroshi Hashiguchi
Takahisa Deguchi
Yoshihiko Nishio
Publikationsdatum
11.04.2019
Verlag
Springer Japan
Erschienen in
Diabetology International
Print ISSN: 2190-1678
Elektronische ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-019-00394-w

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.